Publications by authors named "Te-Sheng Tan"
Subgingival microbiota in individuals with severe chronic periodontitis.
J Microbiol Immunol Infect
April 2018
Background/purpose: Subgingival microorganisms are potentially associated with periodontal diseases. However, the correlation between the variance in the periodontal microbiome and the prevalence and severity of periodontitis remains unclear. The aim of this study was to determine the subgingival microbiota in Taiwanese individuals with severe chronic periodontitis (SP).
View Article and Find Full Text PDFArticle Synopsis
- This study used a 16S rRNA metagenomics approach to analyze bacterial diversity in inanimate hospital environments within a respiratory care center, collecting a total of 16 samples from medical devices and workstations.
- Researchers found a high level of microbial diversity, averaging 1,836 phylotypes per sample, with skin-associated bacteria making up over 60% of the dominant genera, highlighting potential issues in hand hygiene compliance among hospital staff.
- The findings suggest that while Acinetobacter was the most abundant genus in these environments, the study represents the first in Taiwan to reveal significant human-associated bacterial diversity, which may help assess health risks and improve sanitation practices in healthcare settings.
Candida albicans is an opportunistic human pathogen that can form a biofilm on biotic or inert surfaces such as epithelia and clinical devices. In this study, we examine the formation of C. albicans biofilm by establishing a key gene-centered network based on protein-protein interaction (PPI) and gene expression datasets.
View Article and Find Full Text PDFIn recent years, global collaboration has become a conventional strategy for new drug development. To accelerate the development process and shorten approval time, the design of multiregional clinical trials (MRCTs) incorporates subjects from many countries around the world under the same protocol. After showing the overall efficacy of a drug in all global regions, one can also simultaneously evaluate the possibility of applying the overall trial results to all regions and subsequently support drug registration in each of them.
View Article and Find Full Text PDF